A novel protein glycan biomarker and future cardiovascular disease events

Journal of the American Heart Association

Volumn 3, Issue 5, 2014, Pages

  Akinkuolie, Akintunde O ^a   Buring, Julie E ^a   Ridker, Paul M ^a   Mora, Samia ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Cardiovascular; Epidemiology; Glycoproteins; Inflammation

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; GLYCAN; GLYCAN A; UNCLASSIFIED DRUG; POLYSACCHARIDE;

ADULT; ARTICLE; BLOOD PRESSURE; BODY MASS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHRONIC INFLAMMATION; DIABETES MELLITUS; DISEASE ASSOCIATION; ETHNICITY; FEMALE; FOLLOW UP; HEART DEATH; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; MALE; MENOPAUSE; MIDDLE AGED; NORMAL HUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; PROTEIN DETERMINATION; RISK ASSESSMENT; SMOKING HABIT; TURBIDIMETRY; YOUNG ADULT; AGE DISTRIBUTION; AGED; BLOOD; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; GLYCOSYLATION; INCIDENCE; KAPLAN MEIER METHOD; PATHOPHYSIOLOGY; PATIENT SELECTION; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; WOMEN'S HEALTH;

AGE DISTRIBUTION; AGED; BIOMARKERS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CONFIDENCE INTERVALS; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; GLYCOSYLATION; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; PATIENT SELECTION; POLYSACCHARIDES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE; WOMEN'S HEALTH;

EID: 84923074997     PISSN: None     EISSN: 20479980     Source Type: Journal    
DOI: 10.1161/JAHA.114.001221     Document Type: Article

References (31)

1. Marino K, Bones J, Kattla JJ, Rudd PM. A systematic approach to protein glycosylation analysis: A path through the maze. Nat Chem Biol. 2010;6:713-723.
2. van Kooyk Y, Rabinovich GA. Protein-glycan interactions in the control of innate and adaptive immune responses. Nat Immunol. 2008;9:593-601.
3. Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of glycosylation on the biological function and structure of human immunoglobulins. Ann Rev Immuno. 2007;25:21-50.
4. Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and disease. Cell. 2006;126:855-867.
5. Schachter H, Freeze HH. Glycosylation diseases: quo vadis? Biochim Biophys Acta. 2009;1792:925-930.
6. Landsteiner K. Individual differences in human blood. Science. 1931;73:403-409.
7. Shriver Z, Raguram S, Sasisekharan R. Glycomics: a pathway to a class of new and improved therapeutics. Nat Rev Drug Discov. 2004;3:863-873.
8. Arnold JN, Saldova R, Hamid UM, Rudd PM. Evaluation of the serum n-linked glycome for the diagnosis of cancer and chronic inflammation. Proteomics. 2008;8:3284-3293.
9. Gornik O, Lauc G. Glycosylation of serum proteins in inflammatory diseases. Dis Markers. 2008;25:267-278.
10. Bell JD, Brown JC, Nicholson JK, Sadler PJ. Assignment of resonances for 'acute-phase' glycoproteins in high resolution proton nmr spectra of human blood plasma. FEBS Lett. 1987;215:311-315.
11. Ridker PM, Cook NR, Lee IM, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352:1293-1304.
12. Mora S, Otvos JD, Rifai N, Rosenson RS, Buring JE, Ridker PM. Lipoprotein particle profiles by nuclear magnetic resonance compared with standard lipids and apolipoproteins in predicting incident cardiovascular disease in women. Circulation. 2009;119:931-939.
13. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of c-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
14. Mora S, Lee IM, Buring JE, Ridker PM. Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA. 2006;295:1412-1419.
15. Marth JD, Grewal PK. Mammalian glycosylation in immunity. Nat Rev Immunol. 2008;8:874-887.
16. Dube DH, Bertozzi CR. Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov. 2005;4:477-488.
17. Hart GW, Copeland RJ. Glycomics hits the big time. Cell. 2010;143:672-676.
18. Fischer K, Kettunen J, Wurtz P, Haller T, Havulinna AS, Kangas AJ, Soininen P, Esko T, Tammesoo ML, Magi R, Smit S, Palotie A, Ripatti S, Salomaa V, Ala-Korpela M, Perola M, Metspalu A. Biomarker profiling by nuclear magnetic resonance spectroscopy for the prediction of all-cause mortality: an observational study of 17,345 persons. PLoS Med. 2014;11: e1001606.
19. Varki A, Freeze HH. Glycans in acquired human diseases. In: Varki A, Cummings RD, Esko JD, Freeze HH, Stanley P, Bertozzi CR, Hart GW, Etzler ME, eds. Essentials of Glycobiology. Cold Spring Harbor, NY: Cold Spring Harbor;2009: Available at: http://www.ncbi.nlm.nih.gov/books/NBK1946/.
20. Scott DW, Patel RP. Endothelial heterogeneity and adhesion molecules nglycosylation: implications in leukocyte trafficking in inflammation. Glycobiology. 2013;23:622-633.
21. Chacko BK, Scott DW, Chandler RT, Patel RP. Endothelial surface n-glycans mediate monocyte adhesion and are targets for anti-inflammatory effects of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2011;286:38738-38747.
22. Garcia-Vallejo JJ, Van Dijk W, Van Het Hof B, Van Die I, Engelse MA, Van Hinsbergh VW, Gringhuis SI. Activation of human endothelial cells by tumor necrosis factor-alpha results in profound changes in the expression of glycosylation-related genes. J Cell Physiol. 2006;206:203-210.
23. Peng Y, Li J, Geng M. The glycan profile of endothelial cells in the present of tumor-conditioned medium and potential roles of beta-1,6-glcnac branching on huvec conformation. Mol Cell Bbiochem. 2010;340:143-152.
24. Scott DW, Chen J, Chacko BK, Traylor JG Jr, Orr AW, Patel RP. Role of endothelial n-glycan mannose residues in monocyte recruitment during atherogenesis. Arterioscler Thromb Vasc Biol. 2012;32:e51-e59.
25. Yin X, Subramanian S, Hwang SJ, O'Donnell CJ, Fox CS, Courchesne P, Muntendam P, Gordon N, Adourian A, Juhasz P, Larson MG, Levy D. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol. 2014;34:939-945.
26. Cahill LE, Levy AP, Chiuve SE, Jensen MK, Wang H, Shara NM, Blum S, Howard BV, Pai JK, Mukamal KJ, Rexrode KM, Rimm EB. Haptoglobin genotype is a consistent marker of coronary heart disease risk among individuals with elevated glycosylated hemoglobin. J Am Coll Cardiol. 2013;61:728-737.
27. Lee CW, Cheng TM, Lin CP, Pan JP. Plasma haptoglobin concentrations are elevated in patients with coronary artery disease. PLoS One. 2013;8:e76817.
28. Correale M, Totaro A, Abruzzese S, Di Biase M, Brunetti ND. Acute phase proteins in acute coronary syndrome: an up-to-date. Cardiovasc Hematol Agents Med Chem. 2012;10:352-361.
29. Nordestgaard BG, Adourian AS, Freiberg JJ, Guo Y, Muntendam P, Falk E. Risk factors for near-term myocardial infarction in apparently healthy men and women. Clin Chem. 2010;56:559-567.
30. Ahmed MS, Jadhav AB, Hassan A, Meng QH. Acute phase reactants as novel predictors of cardiovascular disease. ISRN Inflamm. 2012;2012:953461.
31. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med. 2000;342:836-843.